Back to Search Start Over

Case Report: Recurrent retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient [version 2; peer review: 2 approved with reservations]

Authors :
Marwa Ben Brahim
Sondes Arfa
Fadia Boubaker
Jihen Chelly
Wafa Ammari
Sonia Hammami
Fatma Arbi
Olfa Berriche
Author Affiliations :
<relatesTo>1</relatesTo>Department of Internal Medicine and Endocrinology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia<br /><relatesTo>2</relatesTo>Department of Ophthalmology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia<br /><relatesTo>3</relatesTo>Department of Internal Medicine and Endocrinology, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, 5000, Tunisia<br /><relatesTo>4</relatesTo>Biochemistry Laboratory,LR12ES05 LR-NAFS Nutrition-Functional Food and Vascular Health, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia
Source :
F1000Research. 10:761
Publication Year :
2021
Publisher :
London, UK: F1000 Research Limited, 2021.

Abstract

Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by widespread clinical manifestations and immunological disorders. A myriad of ocular manifestations can be seen in patients with SLE. The most vision-threatening complication is vaso-occlusive retinopathy including retinal vein occlusion (RVO). RVO associated with SLE is well described in the literature and its association with antiphospholipid antibodies is recognized. However, RVO as the initial manifestation of SLE is scarcely reported. Herein, we report the first case of recurrent RVO as the revealing manifestation of SLE in a 40-year-old male patient. He had two consecutive episodes of decreased vision. Ophthalmologic examination disclosed a branch retinal vein occlusion the first time and a central retinal vein occlusion the second time. The diagnosis of SLE was established based on clinical and immunological criteria. He was prescribed antiplatelet therapy, hydroxychloroquine at 5.5 mg/kg/day, and intravitreal anti-vascular endothelial growth factor (VEGF) antibodies regimen. He slowly improved under treatment.

Details

ISSN :
20461402
Volume :
10
Database :
F1000Research
Journal :
F1000Research
Notes :
Revised Amendments from Version 1 1. Data about the patient medical history was added. 2. We added further details about the laboratory investigations. 3. We have done corrections in the spelling of some words., , [version 2; peer review: 2 approved with reservations]
Publication Type :
Academic Journal
Accession number :
edsfor.10.12688.f1000research.55189.2
Document Type :
case-report
Full Text :
https://doi.org/10.12688/f1000research.55189.2